ERCC1 and gastric cancer: Overall, the pooled HR for the 15 studies was 1.48 (95% CI 1.02–2.10; P=0.036; random-effects model) with significant heterogeneity (Pheterogeneity<0.001, I2=83.8%), suggesting that high/positive ERCC1 expression was an indicator of poor survival in patients with GC.